March
Value Based Healthcare for Life Sciences Made Simple
Unlocking Value Based healthcare: strategies for life sciences to thrive in a patient-centric world.
In this insightful 60-minute masterclass, Andrew Mumford, a global market access expert, will provide a clear overview of the core principles of VBHC and explain how life sciences can effectively integrate these strategies.
How to Make NICE Guidance a Reality for Patients
Navigating the Implications of Mandatory NICE Guidance for Life Sciences
In this 60-minute masterclass for LSAA members, Scott McKenzie will delve into the potential benefits and challenges of mandatory NICE guidance. While the framework could streamline NHS adoption of innovative treatments and improve patient outcomes, it also raises concerns about flexibility, pricing dynamics, and barriers to market entry.
VPAG 2025
Navigating VPAG Changes: Pricing Strategies and NHS Collaboration in 2025
This 60-minute masterclass for LSAA members will provide expert insights into the key trends, challenges, and outcomes observed under VPAG throughout 2024. Our esteemed panel will address the upcoming changes for 2025: focusing on adjustments to payment percentages and the revised exemption threshold for small companies.
April
Navigating NICE: Strategic insights for accelerating market access
Engage early with NICE Advice and accelerate your product’s journey to market
In this 60-minute masterclass for LSAA members with Anna Brett from NICE Advice, discover how you can engage early with NICE and streamline your market access planning.
May
Market Access and the Celtic Nations
Exploring Market Access Trends Across the Celtic Nations
In this 60-minute masterclass, Andrew Mumford, a recognised expert in market access, will provide valuable insights into the latest developments across the Celtic Nations of Scotland, Wales, Northern Ireland and the Republic of Ireland.
Paying for Innovation: First-in-Class vs. Advance-in-Class drugs
In conjunction with the London School of Economics (LSE): How decision-makers perceive different types of pharmaceutical innovation
In this 60-minute masterclass, LSE Professor Panos Kanavos, will explore how HTA agencies assess and reimburse First-in-Class and Advance-in-Class drugs across England, Scotland, France, Germany, Australia, and Canada.
Market Access China 2025: Everything you wanted to know… but were afraid to ask!
Decoding China's Healthcare Landscape: What you need to know
In this 60-minute masterclass, a panel of local market experts will provide insights into China’s unique healthcare dynamics.